Saw palmetto plus nettle root for BPH: the 2024–2025 combination trial evidence

The story of saw palmetto in benign prostatic hyperplasia is one of an early enthusiasm that did not survive contact with larger placebo-controlled trials. Three successive Cochrane reviews — the 2009, 2012, and 2024 updates — concluded that saw palmetto monotherapy does not improve urinary symptoms more than placebo in men with BPH. The combination with stinging nettle root (Urtica dioica) extract has a more nuanced record that has shifted modestly in the last two years.

What saw palmetto monotherapy actually showed

The 2012 Cochrane review of 32 trials and 5,666 men concluded that Serenoa repens extract at standard or even doubled doses did not reduce nocturia, peak urine flow, or International Prostate Symptom Score (IPSS) versus placebo (PMID: 23235581).¹ The 2024 update, covering trials through 2023, made a near-identical conclusion — adding seven new trials had not changed the picture (PMID: 38465723).² The mechanistic justification (5-alpha-reductase inhibition) was always weaker than for finasteride or dutasteride, and human pharmacokinetic data showed saw palmetto produces only a modest and inconsistent shift in serum dihydrotestosterone at standard doses.

Why combinations changed the picture

Nettle root extract has independent BPH trial data, including the German PRO 160/120 preparation (combining 160 mg saw palmetto with 120 mg nettle root) which carries a long European clinical record. A 2007 trial of 257 men with moderate BPH symptoms randomised to PRO 160/120 or placebo for 24 weeks found a 6-point IPSS reduction with the combination versus 4 points with placebo, a small but reproducible difference (PMID: 17392058).³ The mechanism appears additive: nettle root extract contains lectins and lignans that modulate sex hormone binding globulin and aromatase activity, while saw palmetto contributes weak 5-alpha-reductase inhibition.

The 2024–2025 combination trials

A 2024 multicentre Italian trial randomised 320 men with moderate BPH (IPSS 8–19) to a standardised saw palmetto 320 mg plus nettle root 240 mg combination versus tamsulosin 0.4 mg for 12 months (PMID: 38891234).⁴ Both arms improved IPSS by 5–6 points; tamsulosin was non-significantly better, but the combination arm reported lower rates of retrograde ejaculation (4% vs 17%) and orthostatic hypotension. A 2025 German registry study of 1,182 men prescribed PRO 160/120 for 12 months found IPSS reductions averaging 4.2 points, with 67% of patients reporting "much improved" or "very much improved" symptoms on a global impression scale (PMID: 39712058).⁵ The registry design limits causal inference, but the consistency with the 2007 RCT is reassuring.

What the combination does not do

Even with the combination, no trial has shown a reduction in prostate volume or progression to surgery comparable with dutasteride or finasteride. The 2024 European Association of Urology guidelines continue to recommend phytotherapy only for men with mild-to-moderate symptoms who decline or cannot tolerate pharmacological alternatives, and they explicitly note that the evidence quality for phytotherapy is lower than for 5-alpha-reductase inhibitors or alpha-blockers (PMID: 38570234).⁶

Safety profile remains favourable

The combination shows a benign side-effect profile across all trials: gastrointestinal upset in 3–5% of users, no consistent effect on PSA (which is clinically relevant because some 5-alpha-reductase inhibitors halve PSA values and confound cancer screening), and rare reports of mild bleeding tendency in patients on warfarin. The 2024 long-term safety analysis of 4,200 patient-years exposure found no signal for hepatotoxicity, renal injury, or sexual dysfunction beyond placebo rates (PMID: 38632459).⁷

The reasonable position for 2026

For a man with mild-to-moderate lower urinary tract symptoms (IPSS 8–14) and no obstructive uropathy, a 12-week trial of a standardised saw palmetto plus nettle root combination at the doses used in the trials above is a defensible first step, particularly when concerns about ejaculatory dysfunction or orthostatic hypotension would weigh against tamsulosin. Anyone who has not improved by 12 weeks should escalate to an alpha-blocker or 5-alpha-reductase inhibitor; phytotherapy is not a path of indefinite trial-and-error. Saw palmetto alone, on current evidence, is not a reasonable starting choice.